Mental health and wellness company focusing on development, manufacturing and distribution of organic functional mushroom products Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) unveiled a clinical research program focusing on using MDMA-assisted psychotherapy to treat female hypoactive sexual desire disorder.
This will go down as the first ever psychedelics based treatment program focusing at addressing what is clinically called Hypoactive Sexual Desire Disorder (HDD).
HDD is a popular sexual disorder characterized by continuous low sexual desire and emotion distress which cannot be attributed to an existing medical condition or relationship related issues.
Citing compiled data, HDD affects 10% of adult women and 14% of premenopausal adult women. All of the affected adult women cite a state of distress as the reason for low sexual desire.
HDD is also affecting men, however, in the United States, it’s estimated that HDD affects 9.5 million premenopausal women. The company’s president and chief executive officer, Kelsey Ramsden, says that they identified a market gap and are intending to use MDMA-assisted psychotherapy to bridge the gap.
“We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind. Women’s desire issues have not been adequately addressed to date, and we believe that treatment incorporating MDMA and psychotherapy has real promise as it may target those roots of desire in the mind and unlock healing for women lacking desire. Mind Cure has identified a gap in the market, and I think that with the team we have built to execute this project, we can help those seeking improved desire in a new way,” said the CEO.
